METHOD FOR PREPARING MICROCAPSULES WITH LANGERHANS ISLETS AND MICROCAPSULE ACCORDING TO DISCLOSED METHOD Russian patent published in 2024 - IPC A61K35/39 A61K47/32 A61K47/36 A61K9/50 A61P3/10 B01J13/02 

FIELD: biomedicine.

SUBSTANCE: group of inventions can be used to produce preparations for treating and preventing complications of type 1 diabetes mellitus (T1DM). Method for preparation of microcapsules with Langerhans islets (LI) includes: obtaining a suspension of LI by mixing LI with a solution of sodium alginate and dextran with an average molecular weight of 20,000 Da in physiological solution so that the concentration of sodium alginate is 1–3 wt.%, dextran is 15 wt.%, in 1 ml of the suspension is from 5×10³ to 25×10³ LI; using the obtained LI suspension as a dispersed phase and an aqueous solution of PEG-8,000 with concentration of 30 wt.% as a continuous phase, by microfluidics, alginate microcapsules are formed, containing from 1 to 5 islets of Langerhans, which are placed in an aqueous isotonic solution of barium chloride to form a precipitate from cross-linked microcapsules with LI; obtained precipitate is washed and placed in a solution of poly([2-(methacryloyloxy)ethyl]trimethylammonium chloride) with a weight-average molecular weight of 200 to 1,000 kDa in physiological solution with concentration of 0.01 to 3 wt.% for period of 5 to 20 minutes; obtained precipitate is washed and placed in a solution of sodium alginate in physiological solution with concentration of 0.02 to 0.5 wt.% for period of 2 to 10 minutes; obtained microcapsule precipitate is washed and placed in a nutrient medium for subsequent use. Microcapsule obtained using the method described above contains Langerhans islets and three polymer layers: sodium alginate, cationic polymer poly([2-(methacryloyloxy)ethyl]trimethylammonium chloride), sodium alginate.

EFFECT: use of the group of inventions enables to obtain microcapsules having high biocompatibility, ensuring preservation of viability and functional activity of transplanted LI in the recipient's body for a long period of time for effective compensation of insulin deficiency in type 1 diabetes mellitus.

3 cl, 6 dwg, 3 ex